NRSN News

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026PR NewswireCAMBRIDGE, Mass., Oct. 29, 2026 Presentation will...

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury NeuroSense Files U.S. Patent Application for Traumatic Brain InjuryPR NewswireCAMBRIDGE, Mass., Oct. 19, 2026 Patent application seeks protection for PrimeC use in concussion, blast-related brain injury and chronic traumatic...

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding MilestonesPR NewswireCAMBRIDGE, Mass., Oct. 13, 2026Shares continue to trade on Nasdaq pending the Panel's...

NeuroSense Provides Update on Nasdaq Listing Compliance NeuroSense Provides Update on Nasdaq Listing CompliancePR NewswireCAMBRIDGE, Mass., Oct. 2, 2026Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional...

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities ConferencePR NewswireCAMBRIDGE, Mass., Sept. 28, 2026 Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference...

NeuroSense Provides Business Update and Progress for the First Half of 2026 NeuroSense Provides Business Update and Progress for the First Half of 2026PR NewswireCAMBRIDGE, Mass., Sept. 25, 2026 CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ --Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the...

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference PR Newswire CAMBRIDGE, Mass., Sept. 10, 2026 Company presentation on Tuesday, September 15 at 4:30 p.m. ETManagement will be available...

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS PR Newswire CAMBRIDGE, Mass., Aug. 31, 2026 Three-part program - AI-enabled...

Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares increasedread more...